Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Impact of the PPARGC1A Gly482Ser polymorphism on left ventricular structural and functional abnormalities in patients with hypertension

Journal of Human Hypertension volume 28, pages 557–563 (2014)Cite this article

Subjects

Abstract

The Gly482Ser polymorphism in the peroxisome proliferator-activated receptor gamma coactivator-1α (PPARGC1A) has been reported to contribute to the development of left ventricular (LV) hypertrophy. Little is known, however, about its possible impact on cardiac dysfunction. Enhanced myocardial fibrosis accompanying increased LV mass might represent a link with coexisting functional abnormalities. We investigated the association between the PPARGC1A Gly482Ser polymorphism and LV morphology and performance in essential hypertension, with special consideration of fibrosis intensity. A total of 205 hypertensive patients (60±8 years) underwent echocardiography with assessment of cardiac morphology, LV systolic (strain and strain rate) and diastolic function (peak early diastolic mitral flow velocity/peak late diastolic mitral flow velocity (E/A) ratio, peak early diastolic myocardial velocity (Em), and E/e′ ratio (where e′ is the peak early diastolic mitral annular velocity)), evaluation of serum procollagen type III amino-terminal propeptide (PIIINP) and procollagen type I carboxy-terminal propeptide (PICP)—markers of fibrosis and the PPARGC1A Gly482Ser genotyping. Subjects with the Ser–Ser genotype demonstrated more profound LV hypertrophy and diastolic function impairment, and higher PICP/PIIINP than the Ser–Gly and Gly–Gly groups. In multivariable analysis, the presence of the Ser–Ser allele was an independent correlate of E/e′ (β=0.17, P<0.02), Em (β=−0.18, P<0.01) and LV mass index (β=0.28, P<0.001). In conclusion, in hypertensive patients, the PPARGC1A Gly482Ser polymorphism is associated with LV hypertrophy and diastolic dysfunction, with the presence of the Ser–Ser allele promoting these abnormalities. One of the possible mechanisms mediating the adverse effect on diastolic performance might be a relative increase in the anabolism of rigid collagen type I over that of the more elastic collagen type III, as indicated by an increased ratio of PICP to PIIINP.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. de Simone G, Gottdiener JS, Chinali M, Maurer MS . Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 2008; 29: 741–747.

    Article  Google Scholar 

  2. Zile MR, Brutsaert DL . New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002; 105: 1503–1508.

    Article  Google Scholar 

  3. Christoffersen C, Bollano E, Lindegaard ML, Bartels ED, Goetze JP, Andersen CB et al. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 2003; 144: 3483–3490.

    Article  CAS  Google Scholar 

  4. Juang JM, de Las Fuentes L, Waggoner AD, Gu CC, Dávila-Román VG . Association and interaction of PPAR-complex gene variants with latent traits of left ventricular diastolic function. BMC Med Genet 2010; 11: 65.

    Article  Google Scholar 

  5. Weng SW, Lin TK, Wang PW, Chen IY, Lee HC, Chen SD et al. Gly482Ser polymorphism in the peroxisome proliferator-activated receptor gamma coactivator-1alpha gene is associated with oxidative stress and abdominal obesity. Metabolism 2010; 59: 581–586.

    Article  CAS  Google Scholar 

  6. Oberkofler H, Hölzl B, Esterbauer H, Xie M, Iglseder B, Krempler F et al. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men. Hypertension 2003; 41: 368–372.

    Article  CAS  Google Scholar 

  7. Rowe GC, Jiang A, Arany Z . PGC-1 coactivators in cardiac development and disease. Circ Res 2010; 107: 825–838.

    Article  CAS  Google Scholar 

  8. Ingelsson E, Bennet L, Ridderstråle M, Söderström M, Råstam L, Lindblad U . The PPARGC1A Gly482Ser polymorphism is associated with left ventricular diastolic dysfunction in men. BMC Cardiovasc Disord 2008; 8: 37.

    Article  Google Scholar 

  9. Ling C, Del Guerra S, Lupi R, Rönn T, Granhall C, Luthman H et al. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion. Diabetologia 2008; 51: 615–622.

    Article  CAS  Google Scholar 

  10. Vimaleswaran KS, Luan J, Andersen G, Muller YL, Wheeler E, Brito EC et al. The Gly482Ser genotype at the PPARGC1A gene and elevated blood pressure: a meta-analysis involving 13,949 individuals. J Appl Physiol 2008; 105: 1352–1358.

    Article  Google Scholar 

  11. Yang Y, Mo X, Chen S, Lu X, Gu D . Association of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A) gene polymorphisms and type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev 2011; 27: 177–184.

    Article  Google Scholar 

  12. Díez J, Laviades C . Monitoring fibrillar collagen turnover in hypertensive heart disease. Cardiovasc Res 1997; 35: 202–205.

    Article  Google Scholar 

  13. López B, González A, Varo N, Laviades C, Querejeta R, Díez J . Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222–1226.

    Article  Google Scholar 

  14. Picano E, Pelosi G, Marzilli M, Lattanzi F, Benassi A, Landini L et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990; 81: 58–64.

    Article  CAS  Google Scholar 

  15. Ciulla M, Paliotti R, Magrini F . Ultrasonic reflectivity of the heart: a measure of fibrosis? Adv Exp Med Biol 1997; 432: 45–54.

    Article  CAS  Google Scholar 

  16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252.

    Article  CAS  Google Scholar 

  17. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458.

    Article  CAS  Google Scholar 

  18. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 1788–1794.

    Article  CAS  Google Scholar 

  19. Maciejewska A, Sawczuk M, Cieszczyk P, Mozhayskaya IA, Ahmetov II . The PPARGC1A gene Gly482Ser in Polish and Russian athletes. J Sports Sci 2012; 30: 101–113.

    Article  Google Scholar 

  20. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM . Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci USA 2006; 103: 10086–10091.

    Article  CAS  Google Scholar 

  21. Lu Z, Xu X, Hu X, Fassett J, Zhu G, Tao Y et al. PGC-1 alpha regulates expression of myocardial mitochondrial antioxidants and myocardial oxidative stress after chronic systolic overload. Antioxid Redox Signal 2010; 13: 1011–1022.

    Article  CAS  Google Scholar 

  22. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2005; 1: 259–271.

    Article  CAS  Google Scholar 

  23. Lehman JJ, Kelly DP . Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol 2002; 29: 339–345.

    Article  CAS  Google Scholar 

  24. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP . Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996; 94: 2837–2842.

    Article  CAS  Google Scholar 

  25. Brito EC, Vimaleswaran KS, Brage S, Andersen LB, Sardinha LB, Wareham NJ et al. PPARGC1A sequence variation and cardiovascular risk-factor levels: a study of the main genetic effects and gene x environment interactions in children from the European Youth Heart Study. Diabetologia 2009; 52: 609–613.

    Article  CAS  Google Scholar 

  26. Su XL, Dong HR, Yan MR, Cui HW, Yang L, Han FQ . Association between peroxisome proliferator-activated receptor gamma coactivator-1 alpha polymorphism and hypertension in Mongolians in Inner Mongolia. Genet Mol Res 2011; 10: 3930–3936.

    Article  CAS  Google Scholar 

  27. Andersen G, Wegner L, Jensen DP, Glümer C, Tarnow L, Drivsholm T et al. PGC-1alpha Gly482Ser polymorphism associates with hypertension among Danish whites. Hypertension 2005; 45: 565–570.

    Article  CAS  Google Scholar 

  28. Devereux RB, Roman MJ, de Simone G, O'Grady MJ, Paranicas M, Yeh JL et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation 1997; 96: 1416–1423.

    Article  CAS  Google Scholar 

  29. Drazner MH . The progression of hypertensive heart disease. Circulation 2011; 123: 327–334.

    Article  Google Scholar 

  30. Wang S, Fu C, Wang H, Shi Y, Xu X, Chen J et al. Polymorphisms of the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene are associated with hypertrophic cardiomyopathy and not with hypertension hypertrophy. Clin Chem Lab Med 2007; 45: 962–967.

    CAS  PubMed  Google Scholar 

  31. Berk BC, Fujiwara K, Lehoux S . ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117: 568–575.

    Article  CAS  Google Scholar 

  32. Fedak PW, Verma S, Weisel RD, Li RK . Cardiac remodeling and failure From molecules to man (Part II). Cardiovasc Pathol 2005; 14: 49–60.

    Article  CAS  Google Scholar 

  33. Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007; 25: 1958–1966.

    Article  Google Scholar 

  34. Hall CS, Scott MJ, Lanza GM, Miller JG, Wickline SA . The extracellular matrix is an important source of ultrasound backscatter from myocardium. J Acoust Soc Am 2000; 107: 612–619.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. A Rojek and M Cielecka-Prynda: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Cardiology, Wroclaw Medical University, Wroclaw, Poland

    A Rojek, M Cielecka-Prynda, M Przewlocka-Kosmala, A Mysiak & W Kosmala

  2. Department of Endocrinology and Diabetology, Wroclaw Medical University, Wroclaw, Poland

    L Laczmanski

Authors
  1. A Rojek
    View author publications

    Search author on:PubMed Google Scholar

  2. M Cielecka-Prynda
    View author publications

    Search author on:PubMed Google Scholar

  3. M Przewlocka-Kosmala
    View author publications

    Search author on:PubMed Google Scholar

  4. L Laczmanski
    View author publications

    Search author on:PubMed Google Scholar

  5. A Mysiak
    View author publications

    Search author on:PubMed Google Scholar

  6. W Kosmala
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to W Kosmala.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rojek, A., Cielecka-Prynda, M., Przewlocka-Kosmala, M. et al. Impact of the PPARGC1A Gly482Ser polymorphism on left ventricular structural and functional abnormalities in patients with hypertension. J Hum Hypertens 28, 557–563 (2014). https://doi.org/10.1038/jhh.2014.26

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/jhh.2014.26

Search

Advanced search

Quick links